Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Takeda
This is a retrospective, non-interventional study of participants with newly-diagnosed cHL, or with RRHL. The study will review the medical records of participants to describe participant's demographics, disease characteristics, treatments received, outcomes, health resources used by the participants, and adverse events that are associated with treatments, and resources used for treatment.
The study will enroll approximately 50 to 100 participants in each group at each of the 13 participating countries. Based on the diagnosis of the disease, participants will be assigned to one of the following groups:
Group 1: cHL Group 2: RRHL
This multi-center trial will be conducted in Argentina, Australia, China, Colombia, Hong Kong, Mexico, Republic of Korea, Russia, Saudi Arabia, Singapore, South Africa, Taiwan, and Turkey. The data for Group 1 and Group 2 will be collected from date of cHL or RRHL diagnosis until the date of death (or the date when the participant was last known to be alive, whichever occurs first).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Participants newly diagnosed with high-risk stage IIb-IV cHL (for Group 1) or RRHL (for Group 2) between 01 January 2010 and 31 December 2013.
2. Age greater than or equal to (\>=) 18 years at diagnosis of cHL (Group 1) or RRHL (Group 2).
3. Alive or deceased.
4. Written informed consent is obtained for study data collection, where necessary, according to local regulations.
You may not be if
1. Participants for whom the minimum study dataset is not available from their hospital medical records.
2. Participants who have participated in an interventional clinical trial at any stage of their cHL (Group 1) or RRHL (Group 2) management.